Paul Wallace
Director/Board Member at Stroma Biosciences Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Clive Stanway | M | 64 |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | 4 years |
Ingo Ringshausen | M | - |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | 4 years |
Andrew Moore | M | - |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | 4 years |
Fredrik Öberg | M | 59 | 13 years | |
John Beadle | M | - |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | 2 years |
Michale Bouskila-Chubb | M | 48 |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Maris Gunars Hartmanis | M | 71 | 3 years | |
Anna Yvonne Monica Malm Bernsten | F | 63 | 13 years | |
Niklas Prager | M | 54 | 3 years | |
Rolf Classon | M | 79 | 2 years | |
Ronald Eric Long | M | 77 | 4 years | |
Rein Piir | M | 66 | 15 years | |
Jane M. Birgitta Stymne Göransson | F | 67 | 3 years | |
Charlotte Elisabet Edenius | M | 66 | 5 years | |
Christina Kassberg | F | 56 | 15 years | |
Nils-Göran Pettersson | M | 79 | 6 years | |
Björn C. Andersson | M | 78 | - | |
Lars Ivar Robert Adlersson | M | 60 | - | |
Gustav Ingemar Kihlström | M | 72 | 6 years | |
Susana Ayesa Alvarez | M | 54 | 3 years | |
Richard Bethell | M | 61 | - | |
John Öhd | M | 53 | 4 years | |
Henric Juserius | M | 61 | - | |
Anders R. Hallberg | M | 79 | 7 years | |
Åsa Holmgren | F | 59 | - | |
Maria Engström | F | 52 | 2 years | |
Henrik Krook | M | 51 | - | |
Anders Olof Adolf Ekblom | M | 70 | 4 years | |
Jens D. Kristensen | M | 66 | - | |
Per Källblad | M | - | 2 years | |
Håkan Wallin | M | 62 | 5 years | |
Tom Schlossman | M | - | - | |
Börje Darpö | M | - | - | |
Jonas Frick | M | 66 | 6 years | |
Bertil Samuelsson | M | 74 | - | |
Jan Anders Vedin | M | 82 | - | |
Bo Öberg | M | - | 1 years | |
Stina Lundgren | M | 45 | - |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 33 | 86.84% |
United Kingdom | 5 | 13.16% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Wallace
- Personal Network